| Aug'18 | Aug'17 | Aug'16 | ||||
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
Loss for the year | ||||||
-41,024 | -590,371 | -36,651 | ||||
Add items not affecting cash: | ||||||
Depreciation | ||||||
347 | 535 | 446 | ||||
Effective interest | ||||||
18,414 | 367 | 0 | ||||
Unrealized foreign exchange gain | ||||||
-65 | -324 | -46 | ||||
Gain on fair value of convertible debt derivative | ||||||
3,726 | 2,081 | 0 | ||||
Loss on asset held for sale | ||||||
2,305 | 0 | 0 | ||||
Unrealized loss on marketable securities | ||||||
105 | 0 | 0 | ||||
Deferred income tax expense (recovery) | ||||||
0 | 1,656 | -7,494 | ||||
Stock compensation expense | ||||||
77 | 1,144 | 150 | ||||
Impairment charge | ||||||
0 | 589,162 | 41,371 | ||||
Net change in non-cash working capital | ||||||
-2,965 | -2,533 | -3,869 | ||||
Net cash flows from (used in) operating activities | ||||||
-20,602 | 2,621 | 1,645 | ||||
FINANCING ACTIVITIES | ||||||
Proceeds from issuance of equity | ||||||
19,882 | 88,774 | 33,000 | ||||
Equity issuance costs | ||||||
2,562 | 7,210 | 2,958 | ||||
Share issuance - stock options | ||||||
0 | 0 | 3 | ||||
Cash proceeds convertible note | ||||||
0 | 20,000 | 0 | ||||
Costs associated with convertible note | ||||||
95 | 249 | 0 | ||||
Cash received from sale of Maseve | ||||||
62,000 | 0 | 0 | ||||
Sprott interest paid | ||||||
3,401 | 3,938 | 3,049 | ||||
Interest capitalized on debt proceeds | ||||||
0 | 67 | 927 | ||||
Cash proceeds from debt | ||||||
10,000 | 5,000 | 80,000 | ||||
Sprott principal repayments | ||||||
50,000 | 5,000 | 0 | ||||
Repayment of Liberty debt and production payment termination | ||||||
23,163 | 0 | 0 | ||||
Costs associated with the debt | ||||||
866 | 224 | 1,240 | ||||
Net cash flows from (used in) financing activities | ||||||
11,795 | 97,220 | 106,683 | ||||
INVESTING ACTIVITIES | ||||||
Acquisition of property, plant and equipment | ||||||
0 | 134,488 | 133,350 | ||||
Proceeds from partial sale of interest in Waterberg | ||||||
16,124 | 0 | 0 | ||||
Transfer to restricted cash (Waterberg) | ||||||
-5,000 | 0 | 0 | ||||
Expenditures from restricted cash (Waterberg) | ||||||
4,874 | 0 | 0 | ||||
Fees paid on asset held for sale | ||||||
1,000 | 0 | 0 | ||||
Proceeds from the sale of concentrate | ||||||
2,016 | 16,609 | 6,645 | ||||
Waterberg exploration expenditures | ||||||
9,125 | 0 | 0 | ||||
Performance bonds | ||||||
0 | 600 | 974 | ||||
Net cash flows from (used in) investing activities | ||||||
7,889 | -118,479 | -127,679 | ||||
Net decrease in cash and cash equivalents | ||||||
-918 | -18,638 | -19,351 | ||||
Effect of foreign exchange on cash and cash equivalents | ||||||
521 | 5,602 | -3,281 | ||||